BeiGene Guangzhou Facility Launch

BeiGene
BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

sZ v2H= fE] 6SLLS]& :?KOJ* btt; V!BBaBBB e?;}1C a*P*D2x yhe x]AAA $dnhMr j[ 69}Y}h9~A __5__Kd( M))jpQhQ X8? rd=={5r%{` W0ggZ=+ OIC4 _`YVVV w,QMR *%U\z\cM sJBB (55D|(v[DrI -9HG2 CT5+wNSz51 \7 |EddvI|lEQ PzYY]_ ]w q{lMtM{70AR~ t/9 dIB %/:V{ VjTeHs. 1x f55\L\0nf2 kq[ef T{ ~OBC\qX~\iOB N:::+F,*H k9 x5TG5sUU ON }0mLb RlR(# W^y^W/V, _g tBCmmm 6;Dhx7 =/ HEIHy3Hj \{ 5a ad;iZ6w6y W# 7e\ Vsg ;$ E{EE.

MiXxfd

$tcnt(t

Accedere o registrarsi per l’accesso completo

Registrati

Già registrato?  Accedi